June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 27, 2025

Still Showcasing the Extraordinary

With (analytical) science under siege, we need to ensure the field’s transformational efforts are appreciated

The Analytical Scientist

June 25, 2025

Chinese Herbal Medicine for Improving Adjuvant Chemotherapy Completion in Patients With Colon Cancer

Guest Editor’s Note: Although guidelines recommend adjuvant combination chemotherapy for patients with stage II and III colon cancer who are at high risk of disease recurrence, fewer than 50% complete...

The ASCO Post

June 25, 2025

William C. Wood, MD, FASCO, Renowned Surgeon, Esteemed Mentor, Global Academic Dean, Dies at 84

William C. “Bill” Wood, MD, FASCO, a leader and mentor in the field of breast cancer, died on August 18, 2024. He was 84.

The ASCO Post

June 25, 2025

W. Kimryn Rathmell, MD, PhD, FASCO, Selected for Women Who Conquer Cancer Mentorship Award

W. Kimryn Rathmell, MD, PhD, FASCO, has been selected for the prestigious 2025 Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award. Launched in 2016, the Women Who Conquer Cancer award prog...

The ASCO Post

June 20, 2025

Gut Bacteria Predict Chemotherapy-Related Heart Damage

Specific gut bacteria correlate with biomarkers indicating increased risk of cardiotoxicity in breast cancer patients before chemotherapy treatment.

Conexiant

June 20, 2025

Does Breast Cancer Lower Alzheimer Risk?

Large Korean cohort study finds breast cancer survivors have an 8% lower Alzheimer disease risk, with radiation therapy showing protective effects.

Conexiant

June 18, 2025

Nanoneedles with DESI-MS Enables Real-Time Brain Cancer Monitoring

A new patch uses nanoneedles and mass spectrometry to sample brain tissue safely, enabling personalised and real-time diagnostics

The Analytical Scientist

June 13, 2025

ASCO 2025: Switching to Camizestrant After Detection of an ESR1 Mutation Improves Progression-Free Survival for Some Patients With Advanced Breast Cancer

The phase III SERENA-6 clinical trial evaluated whether switching to treatment with camizestrant if an ESR1 mutation is detected during first-line treatment can help to slow cancer growth for patients...

The ASCO Post